Stock Market Wire News Logo
Stock Market Wire News Logo
    • Login
    • Sign Up

Ad

Investor Relations

AGEN Message Board | Agenus Inc.


home / stock / agen / agen message board

AGEN AGEN Quote AGEN Short AGEN News AGEN Articles AGEN Message Board
New Post

Message Board | Agenus Inc. (NASDAQ:AGEN)

Subject By Source When
whytestocks: $AGEN News Article - Agenus Selected for Late-Breaking Oral Presentation at ESMO-GI whytestocks investorshangout 05/03/2023 6:35:51 PM
shalbyj: TheStreetReports: AI Biotech Stocks to Watch 2023: $IPA, $ONTX, $AGEN, $PBIO https://www.ma shalbyj investorshangout 04/25/2023 1:37:15 PM
whytestocks: $AGEN News Article - Agenus Receives Fast Track Designation for Botensilimab and Balsti whytestocks investorshangout 04/17/2023 12:00:59 PM
whytestocks: $AGEN News Article - Agenus' Botensilimab in Combination with Balstilimab Shows 33% Dur whytestocks investorshangout 03/27/2023 3:10:50 PM
whytestocks: $AGEN News Article - Best Penny Stocks To Buy Now: 3 To Watch Before Next Week whytestocks investorshangout 03/15/2023 8:20:47 PM
whytestocks: $AGEN News Article - Agenus to Present Botensilimab Data in Oral Plenary Session at the whytestocks investorshangout 02/28/2023 6:50:48 PM
whytestocks: $AGEN News Article - Agenus to Provide Corporate Update and Fourth Quarter & Full Year whytestocks investorshangout 02/28/2023 6:45:53 PM
... B.Riley psswd is in immediate registration confirmation Doktornolittle investorshub 01/23/2023 1:39:04 PM
B Riley would not allow me to view Doktornolittle investorshub 01/19/2023 4:00:47 PM
SITC Oral Presentation on BOT w/wo BAL tomorrow Doktornolittle investorshub 11/11/2022 1:21:03 PM
whytestocks: $AGEN News Article - Agenus to Provide Corporate Update and Second Quarter 2022 Financi whytestocks investorshangout 07/27/2022 12:35:53 PM
znewcar1: AGEN 22% v11,5M c2.41 f282,8M H2.42 ML1.25 znewcar1 investorshangout 07/05/2022 8:23:15 PM
whytestocks: $AGEN News Article - Agenus to Participate at William Blair's Biotech Focus Conference whytestocks investorshangout 06/30/2022 12:35:50 PM
znewcar1: AGEN 2% $1.64 v2M+f271M was 183M 21M ago. 50 AGEN 23% v19,8M c5.19 f183M H5.3809/10/2020 znewcar1 investorshangout 06/03/2022 7:47:02 PM
whytestocks: $AGEN News Article - Agenus Corporate Update and First Quarter 2022 Financial Report whytestocks investorshangout 05/10/2022 5:35:49 PM
whytestocks: $AGEN News Article - Agenus to Provide Corporate Update and Fourth Quarter & Full Year whytestocks investorshangout 02/15/2022 9:45:54 PM
$AGEN Agenus initiated with a Buy at H.C. Wainwright stockguard investorshub 12/16/2021 1:24:16 PM
$11 from $12. Buy rating. Analyst has been north40000 investorshub 12/07/2021 4:09:37 AM
what was the B Riley target price? investtemp investorshub 12/06/2021 8:34:01 PM
B. Riley bullish on Novavax, Agenus amid Omicron stockguard investorshub 12/06/2021 8:11:10 PM
Next
Stock Information

Get AGEN Alerts

News, Short Squeeze, Breakout and More Instantly...

Agenus Inc. Company Name:

AGEN Stock Symbol:

NASDAQ Market:

-0.21% G/L:

$5.18 Last:

903,672 Volume:

$4.87 Open:

$5.18 Close:

Agenus Inc. Website:

Agenus Inc. Logo

Ad

Investor Relations
RECENT AGEN NEWS
  • AGEN - Investors Turn to Cancer Breakthroughs as Federal Funding Faces Deep Cuts

    Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – Baystreet.ca News Commentary – With cancer cases rising and treatment costs hitting new highs, the private sector is under growing pressure to lead the next wave of innovation. Experts are now sounding...

  • AGEN - Agenus' BOT/BAL Achieves 42% Two-Year Survival in Refractory MSS CRC, Advances Toward Registration with FDA Alignment on Phase 3

    Agenus Inc. (Nasdaq: AGEN) a leader in immuno-oncology innovation, today announced that its botensilimab and balstilimab (BOT/BAL) combination achieved a two-year survival rate of 42% along with a now more mature 21-month median overall survival (OS) in an expanded cohort of 123 patients with mic...

  • AGEN - Investors Bet on Biotech as Public Cancer Research Hits a Wall

    Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – Baystreet.ca News Commentary – As cancer rates continue to climb worldwide, the race to develop better, faster, and more affordable treatments has never been more urgent. Industry forecasters now proje...

  • Research
  • Stock Search
  • News Releases
  • Articles
  • Topics
  • Message Boards
  • Trending Stocks
  • Trending Feed
  • Trending Alerts
  • Watchlist
  • Short Information
  • Stock Wall
  • Link Twitter
  • Sign Up
  • Login
  • Contact

Link your X Account

Link your X Account to Market Wire News

When you linking your X Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your X account.

Be alerted of any news about your stocks and see what other stocks are trending.



Connect with Us

Join our Telegram Alerts Channel

Telegram

Join our Discord

Discord

Get AGEN Alerts

Get AGEN Alerts

News, Short Squeeze, Breakout and More Instantly...

Sign up or login to continue

Sign up or login to continue.


Forgot password?




Mobile Number Subscribers

Market Wire News provides notifications to customers about updates, service, reminders, or products. Current and new customers of Market Wire News will enter their mobile numbers on a web opt-in form https://marketwirenews.com. Supported Carriers are as follows Alltel, AT&T, Cincinnati Bell, Dobson Cellular Systems, Inter Op, MetroPCS®, Nextel Communications, Sprint PCS, T-Mobile®, U.S. Cellular®, Verizon Wireless, and Virgin Mobile U.S. T-Mobile® is not liable for delayed or undelivered messages. There are no premium charges for joining Market Wire News service. Message and data rates may apply. Subscribers to Market Wire News service may receive up to 500 per month.

How to Opt Out

To opt-out of the Market Wire News program, send or text STOP, END, QUIT, CANCEL or UNSUBSCRIBE to (844) 931-3999. An unsubscribe message will be sent to your number confirming the cancellation, but no more messages will be sent after that one.

Mobile Support

For support or information about a Market Wire News, send or text HELP to (844) 931-3999. Optionally, you may email support@marketwirenews.com.


Disclaimer

This electronic content is for the purposes of solicitation subscriptions for Market Wire News. Market Wire News expects to generate new advertisement revenue resulting from the distribution of this electronic content. The amount of which is unknown at this time. Market Wire News is not a registered investment adviser or broker-dealer. This electronic content does not provide a professional analysis of a any stock financial position. any stock's financial position and all other information regarding the featured Company should be verified directly with any stock. This electronic content is provided as an information service only, and any statements and opinions in this electronic content should not be construed as an offer or solicitation to buy or sell any security. Market Wire News accepts no liability for any loss arising from an investor's reliance on or use of this electronic content. An investment in any company is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. Market Wire News does not own, buy, sell or plans to own, buy, sell, and of any stock's shares. This electronic content contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Please read our full disclaimer for compensation and more detailed information.

Advertise

Brand your company, advertise your products or services with our ad programs.

Advertise

Research

Stock Search

News Releases

Articles

Message Boards

Trending Stocks

Short Information

Stock Wall

Members

Log In

Sign Up

Stay Connected

| X

| Facebook

| BlueSky

| LinkedIn

| Telegram

| Discord


Contact

Privacy

Terms of Service

Disclaimer

© 2025 Market Wire News 1